Article Text

Download PDFPDF

2022-RA-1264-ESGO Evaluation of managing CIN 3 plus diagnosed pregnant women by methylation assessment using FAM19A4/miR124 methylation test
  1. Monika Hampl1,
  2. Bart Hesselink2,
  3. Chris Meijer3,
  4. Agnieszka Denecke4,
  5. Ina Einhorn5,
  6. Matthias Jentschke6,
  7. Martin Koch7,
  8. Frederik Stuebs8,
  9. Linn Wölber9,
  10. Karl Ullrich Petry10,
  11. Studiengruppe Kolposkopie and
  12. Peter Hillemanns6
  1. 1Obstetrics and Gynecology, University Hospital of Düsseldorf, Düsseldorf, Germany
  2. 2Self screen B.V., Amsterdam, Netherlands
  3. 3Pathology, University Medical center Amsterdam, Amsterdam, Netherlands
  4. 4Ostretrics and Gynecology, University Medical Center Hannover, Hannover, Germany
  5. 5Obstetrics and Gynecology, Klinikum Wolfsburg, Wolsburg, Germany
  6. 6Obstetrics and Gynecology, University Medical Center Hannover, Hannover, Germany
  7. 7Frauenklinik, ANregio, Ansbach, Germany
  8. 8Dept. of Obstetrics and Gynecology, Universitätsklinikum, Erlangen, Germany
  9. 9Dept. of Obstetrics and Gynecology, University Medical Center, Hamburg, Germany
  10. 10Obstetrics and Gynecology, Klinikum Wolfsburg, Wolfsburg, Germany


Introduction/Background Pregnant women diagnosed with CIN3 (cervical intraepithelial neoplasia) have high regression rates after delivery. Biomarkers are needed to only identify pregnant women with progressive CIN requiring treatment to reduce over referral and overtreatment.

Methodology In this study we evaluated the performance of the FAM19A4/miR124–2 methylation test for molecular triage on formalin fixed samples of CIN3+-diagnosed pregnant women with known clinical course over time as well in a cross-sectional setting. In this German multicenter retrospective study biopsy material was collected from pregnant women diagnosed with cervical cancer (n=16), with CIN3 that progressed to cancer during pregnancy (n=7), with CIN3 that regressed to CIN1 or less within 6 months after delivery (n=41), without CIN (n=16), CIN3 covering 3–4 quadrants (n=14) and randomly selected CIN3 (n=41). FAM19A4/miR124–2 methylation analysis was performed blinded on first diagnosis.

Results All pregnant women with cervical cancer and with CIN3 progressing to cancer tested positive for FAM19A4/miR124–2 methylation (100%, 22/22). In the regressing CIN3 group 47.5% and in the group without CIN 21.6% tested methylation positive. High-volume CIN3 and random selected CIN3 were methylation-positive in 91.7% and 82.1%. Methylation levels were significantly higher in progressive CIN3 and cancer compared to the controls (P<0.0005). The likelihood ratio of a negative methylation test (LR-) for progressive CIN3+ was 0 (95%CI:0–0.208).

Conclusion A negative FAM19A4/miR124–2 methylation test can rule out progressive CIN disease in pregnant women diagnosed with CIN3. This can help the clinician by managing these pregnant women with conservative follow-up until after delivery. (Int J Cancer. 2022 Jun 6. doi: 10.1002/ijc.34153)

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.